Epitalon (Epithalon) vs Ipamorelin

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

Epitalon (Epithalon)Ipamorelin
CategoryPeptidesPeptides
Standard DoseResearch indicates 5-10 mg daily via subcutaneous injection for 10-20 day cycles.Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection.
TimingEvening administration preferred (aligns with pineal/melatonin function). Some protocols split doses AM/PM.Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach.
Cycle Duration10-20 day intensive cycles repeated every 4-6 months. Not used continuously.12-24 week cycles with 4-8 week breaks.
Evidence Levelanimal_plus_anecdotalmoderate_human

Mechanism

Epitalon (Ala-Glu-Asp-Gly / AEDG) is a synthetic tetrapeptide based on the natural pineal gland peptide epithalamin. It activates telomerase by inducing expression of the catalytic subunit hTERT, resulting in telomere elongation averaging 33.3% in human somatic cells. Epitalon restores pineal melatonin synthesis and circadian gene expression in aged organisms, increases BDNF, and upregulates CREB1. It also modulates the neuroendocrine system through its effects on the hypothalamic-pituitary axis and antioxidant enzyme regulation.

Standard Dosing

Research indicates 5-10 mg daily via subcutaneous injection for 10-20 day cycles.

Timing

Evening administration preferred (aligns with pineal/melatonin function). Some protocols split doses AM/PM.

Cycle Duration

10-20 day intensive cycles repeated every 4-6 months. Not used continuously.

Side Effects

  • Injection site irritation
  • Mild drowsiness (evening dosing)
  • Vivid dreams

Contraindications

  • Active cancer (telomerase activation concern)
  • History of cancer within 5 years
  • Pregnancy and breastfeeding

Best Stacking Partners

GHK-CuMOTS-cHumanin
B

Ipamorelin

Peptides

Mechanism

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as the first selective growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) agonist. Unlike other GHRPs, it selectively stimulates GH release without significantly affecting ACTH, cortisol, prolactin, or aldosterone — even at doses 200-fold above the ED50 for GH release. This selectivity profile is comparable to GHRH itself but operates through the distinct ghrelin receptor on pituitary somatotrophs.

Standard Dosing

Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach.

Cycle Duration

12-24 week cycles with 4-8 week breaks.

Side Effects

  • Head rush post-injection
  • Mild hunger increase (less than GHRP-6)
  • Water retention (mild)
  • Tingling in extremities
  • Injection site irritation

Contraindications

  • Active cancer
  • Diabetic retinopathy
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)BPC-157TB-500

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →